Form 4: Zimmer Biomet Executive Earns 4,843 Performance RSUs

Zimmer Biomet Holdings, Inc. officer Wilfred Van Zuilen earned 4,843 performance-based Restricted Stock Units, vesting on March 6, 2026.

Summary

• Wilfred Van Zuilen, Group President, EMEA, of Zimmer Biomet Holdings, Inc. (ZBH), earned 4,843 Restricted Stock Units (RSUs).
• These RSUs were initially granted on March 6, 2023, as performance-based awards, with the number earned contingent on meeting specific performance conditions over the 2023-2025 period.
• The determination that 4,843 RSUs were earned, based on actual performance, was made on February 19, 2026.
• Each RSU represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock.
• The earned RSUs are scheduled to vest on March 6, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting the successful achievement of performance targets by a key executive, which aligns executive incentives with shareholder interests.

Positives

• Wilfred Van Zuilen successfully met performance conditions for the 2023-2025 period, resulting in the earning of 4,843 performance-based Restricted Stock Units.
• The vesting of these RSUs on March 6, 2026, will increase the executive's direct ownership in Zimmer Biomet Holdings, Inc., aligning management and shareholder interests.

Future Outlook

The 4,843 earned Restricted Stock Units are scheduled to vest on March 6, 2026, at which point they will convert into shares of Zimmer Biomet Holdings, Inc. common stock.

Industry Context

StockSavvy.ai notes that performance-based RSU grants are a common executive compensation tool in the medical device industry, aligning executive incentives with long-term company performance and shareholder value.

Comparison to Industry Standards

• Performance-based equity awards, such as these RSUs, are a standard component of executive compensation packages across the medical technology sector, including peers like Stryker Corporation and Johnson & Johnson MedTech.
• The structure, tying vesting to multi-year performance metrics (2023-2025), is consistent with best practices for incentivizing sustained growth and operational excellence within the industry.

Stakeholder Impact

• Shareholders: The vesting of RSUs will result in a slight dilution of existing shares, but the underlying performance achievement is generally positive. It also aligns executive interests with shareholder value.
• Employees: May signal successful company performance and a commitment to performance-based incentives within the organization.

Next Steps

• The 4,843 earned RSUs will vest on March 6, 2026, converting into shares of Zimmer Biomet Holdings, Inc. common stock.

Key Dates

Recommendation

This Form 4 reports a routine executive compensation event where performance-based Restricted Stock Units were earned and are set to vest. It does not provide new material information that would significantly alter the investment thesis for Zimmer Biomet Holdings, Inc., thus a 'hold' recommendation remains appropriate based solely on this filing.

Keywords

Zimmer Biomet, ZBH, Form 4, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, Wilfred Van Zuilen